Structure via PubChem · Public domain (PubChem)
selumetinib
Sign in to saveAlso known as NSC 741O78, ARRY-886, AZD-6244, ARRY-142886, Koselugo, AZD 6244, AZD6244, ARRY142886
Selumetinib (International nonproprietary name|), sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. It is taken by mouth.
Chemical data
- Formula
- C17H15BrClFN4O3
- Molecular weight
- 457.7 g/mol
- IUPAC name
- 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
- SMILES
- CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
- InChIKey
- CYOHGALHFOKKQC-UHFFFAOYSA-N
- XLogP
- 3.6
- Polar surface area
- 88.4 Ų
- H-bond donors
- 3
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- multiple myeloma, neoplasm, non-small cell lung carcinoma, cutaneous melanoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 456
- Has use
- medication
Show 4 more facts
- chemical formula
- C₁₇H₁₅BrClFN₄O₃
- canonical SMILES
- CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
- World Health Organisation international non-proprietary name
- selumetinib
- subject has role
- protein kinase inhibitors
via Wikidata · CC0
~9 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Adverse effects
- Pregnancy
- Interactions
- Pharmacology
- Mechanism of action
- History
- Research
- References
- Further reading
- External links
Selumetinib (International nonproprietary name|), sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. It is taken by mouth.
Common side effects include headache, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle pain, as well as dry skin and other skin problems.
Excerpted from Wikipedia’s “selumetinib” article, available under the CC BY-SA 4.0 licence.